Insulin resistance in amyotrophic lateral sclerosis

https://doi.org/10.1016/0022-510X(84)90154-0Get rights and content

Abstract

Over the last 30 years glucose intolerance has been reported in a significant percentage of patients with amyotrophic lateral sclerosis (ALS). Currently, a controversy exists in determining whether the carbohydrate abnormality is disease-specific or secondary to decreased glucose utilization due to muscle atrophy. A reduction in glucose receptor space had been postulated for a number of neuromuscular diseases including ALS. In order to clarify this issue we have estimated in vivo insulin sensitivity, using the euglycemic insulin clamp technique, in ALS patients and two control groups, matched according to percent ideal weight. The results showed that the glucose infusion rate, an estimate of in vivo insulin sensitivity, was significantly diminished in ALS patients compared to both normal and disease controls. These results demonstrate that the insulin resistance in this disorder cannot be explained by a decrease in glucose-receptor space and suggest a primary carbohydrate aberration in the disease process itself.

References (20)

There are more references available in the full text version of this article.

Cited by (0)

Supported in part by a grant from the Muscular Dystrophy Association, the ALS Society of America, the ALS Regional Research Center of the University of Kansas College of Health Sciences, and by BRSG SO7 RR 05373, awarded by the Biomedical Research Support Grant Program, Division of Research Resources, NIH.

Present address: Metabolic and Developmental Neurology Branch, NINCDS, NIH, Bethesda, MD 20205, U.S.A.

∗∗

Present address: University of Illinois at the Medical Center, Chicago, IL, U.S.A.

View full text